Globus MedicalGMED
About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Employees: 5,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $3.38M
2% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 53
1% less funds holding
Funds holding: 446 [Q2] → 442 (-4) [Q3]
2% less capital invested
Capital invested by funds: $7.95B [Q2] → $7.79B (-$162M) [Q3]
6.72% less ownership
Funds ownership: 103.1% [Q2] → 96.39% (-6.72%) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 174
18% less funds holding in top 10
Funds holding in top 10: 22 [Q2] → 18 (-4) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Canaccord Genuity William Plovanic 71% 1-year accuracy 35 / 49 met price target | 20%upside $101 | Buy Maintained | 10 Jan 2025 |
B of A Securities Craig Bijou 43% 1-year accuracy 3 / 7 met price target | 16%upside $97 | Neutral Upgraded | 9 Jan 2025 |
Truist Securities Richard Newitter 74% 1-year accuracy 31 / 42 met price target | 7%upside $90 | Hold Maintained | 18 Dec 2024 |
Roth MKM Jason Wittes 58% 1-year accuracy 11 / 19 met price target | 37%upside $115 | Buy Maintained | 17 Dec 2024 |
BTIG Ryan Zimmerman 68% 1-year accuracy 32 / 47 met price target | 8%upside $91 | Buy Maintained | 12 Dec 2024 |
Financial journalist opinion
Based on 11 articles about GMED published over the past 30 days









